^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Jemperli (dostarlimab-gxly) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy
Published date:
08/01/2024
Excerpt:
On August 1, 2024, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with primary advanced or recurrent endometrial cancer (EC).
